On January 6, 2022 Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, reported it will be featured as a presenting company at the H.C. Wainwright Bioconnect Conference (Press release, Nuvo Pharmaceuticals, JAN 6, 2022, https://www.miravohealthcare.com/news/miravo-healthcare-announces-participation-at-the-h-c-wainwright-bioconnect-conference/ [SID1234598346]). The conference is being held as a virtual conference on January 10-13, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jesse Ledger, Miravo’s President & Chief Executive Officer and Mary-Jane Burkett, Miravo’s Vice President & Chief Financial Officer, will be providing an overview of the Company’s business during the presentation. If you are an institutional or retail investor and would like to listen to the Company’s presentation, please click on the following link (View Source) to register for the conference. Corporate presentations and panels are available live and on-demand on January 10, 2022, starting at 7:00 a.m. ET.

Event: H.C. Wainwright Bioconnect Conference (Virtual Conference)

Date: January 10-13, 2022

Time: Available for on-demand viewing starting at 7:00 a.m. ET January 10th

Company Webcasting Link: View Source

About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com.

On January 6, 2022 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that the Company will deliver a corporate presentation at the upcoming virtual investor conferences below (Press release, Soligenix, JAN 6, 2022, View Source [SID1234598345]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright BioConnect Conference, held January 10 through 13, 2022 with presentations, one-on-one meetings, and networking. The on-demand presentation will be available Monday, January 10 at 7AM ET. To view the presentation, please go to View Source The presentation will be archived there for 90 days. For more information about the H.C. Wainwright BioConnect Conference, please refer to the conference website at View Source
Biotech Showcase: The Investor Conference for Innovators, held January 10 through 12, and 17 through 19, 2022 with presentations, one-on-one meetings, and networking. The presentation will be available for registered attendees beginning Monday, January 10. For more information about the Biotech Showcase Conference, please refer to the conference website at https://informaconnect.com/biotech-showcase/.
Key members of Soligenix management will hold one-on-one meetings throughout both conferences. Registered conference attendees may schedule a meeting with Soligenix via the conference scheduling platform.

If you are unable to attend the conferences and would like to schedule a meeting with management, please contact [email protected].

On January 6, 2022 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, reported that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, taking place January 10-13, 2022 (Press release, Galera Therapeutics, JAN 6, 2022, https://investors.galeratx.com/news-releases/news-release-details/galera-present-hc-wainwright-bioconnect-conference [SID1234598344]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available for on-demand viewing on January 10, 2022 at 7:00 a.m. ET on the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the News & Events section of the Investors page of Galera’s website for 30 days following the event.

On Januaryn 6 2022 Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, reported that management will participate in the virtual 40th Annual J.P. Morgan Healthcare Conference (Press release, Immunocore, JAN 6, 2022, View Source [SID1234598343]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation is scheduled for Wednesday, January 12, 2022 at 7:30 a.m. Eastern Time (ET).

The presentation and Q&A session will be webcast live during the conference and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentation and Q&A session will be made available for a limited time.

On January 6, 2022 Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, reported that Bill Newell, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 13, 2022, at 11:15 a.m. ET / 8:15 a.m. PT (Press release, Sutro Biopharma, JAN 6, 2022, View Source [SID1234598342]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. A replay of the webcast will be available for approximately 30 days following the event.